Precision Medicine

Precision medicine tailors treatments to the needs of individual patients by considering genetic, environmental and lifestyle factors. They can target the underlying causes of a patient’s condition, improve effectiveness, and reduce side effects.

Personalised Medicine: is it an Oil-Rush or Oil-Spill?
Publication

Personalised Medicine: is it an Oil-Rush or Oil-Spill?

1 May 2020

Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct…

News

Our Contributions to the Economics of Personalised Medicine

7 March 2018

OHE has authored numerous papers on personalised medicine with contributions to value frameworks, innovations in pricing and cost effectiveness analyses.

News

Value and Cancer: Journal of Cancer Policy Special Issue

25 January 2017

A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.

Publication

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

5 July 2016

“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.

News

OHE’s Paula Lorgelly Appointed as a Visiting Professor at King’s College London

20 June 2016

Paula Lorgelly has accepted an appointment as a Visiting Professor in the Division of Cancer Studies at King’s College London.

News

OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value

29 October 2014

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The…

Prof Towse on valuing genomic medicines and diagnostics
News

Personalised Medicine and the Value of Molecular Diagnostics: Case Studies

18 December 2013

Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in…

Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
News

Personalised Medicine: Economic Incentives for Evidence Generation

28 October 2013

Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison,…

News

OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping

6 August 2013

OHE was involved in several sessions at the 9th World Congress of the International Heath Economics Association (iHEA). Prof Adrian Towse, OHE’s Director, and Prof Lou…